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Extracorporeal membrane oxygenation for overwhelming
Blastomyces dermatitidis pneumonia
Heidi J Dalton, James H Hertzog, Robert L Hannan*, Phyllis Vezza†
and Gabriel J Hauser
Blastomyces dermatitidis is a fungus that is found primarily in endemic areas of
the midwestern and southcentral USA. Blastomycosis pneumonia may develop
after the inhalation of spores. While blastomycosis may lead to acute or chronic
pneumonitis, it will rarely result in the development of the acute respiratory
distress syndrome (ARDS). In this situation, mortality rates are 50–80%. Patients
who survive, however, commonly show good recovery of pulmonary function.
Extracorporeal membrane oxygenation (ECMO), a modified form of
cardiopulmonary bypass that allows systemic perfusion, oxygenation, and carbon
dioxide removal, may be used to support patients with cardiorespiratory failure
that is refractory to conventional therapies. The use of ECMO allows the reduction
of high levels of mechanical ventilatory support that may cause iatrogenic injury to
the diseased lung. Fungal diseases are often contraindications for ECMO use,
since systemic fungal organisms may bind to the ECMO circuit and be difficult to
eradicate. It may be reasonable to utilize ECMO, however, if the fungal infection is
isolated to the respiratory system. We report the case of a patient with ARDS
secondary to blastomycosis pneumonia who was treated with ECMO due to the
failure of conventional cardiorespiratory supports. To our knowledge, this is the
first report of the use of ECMO for this condition.
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Introduction
Blastomyces dermatitidis, a fungus that is endemic to the
midwestern and southcentral USA, is a relatively common
cause of pulmonary and cutaneous mycosis in these areas.
Both respiratory and extrapulmonary infections are com-
monly initiated with the inhalation of fungal spores. Fol-
lowing the introduction of amphotericin B, the fatality rate
has fallen from 78% to between 21–28%. If a total dose of
2g amphotericin B is given, the cure rate may rise to 97%
[1]. However, if blastomycosis pneumonia is associated
with the development of the acute respiratory distress syn-
drome (ARDS), the mortality rate rises to 50%–80% [2].
Extracorporeal membrane oxygenation (ECMO) has been
used successfully to support newborn, pediatric and adult
patients with cardiac and respiratory diseases that are
refractory to conventional therapy. Survival rates of 80%
have been achieved in the 13000 neonates who have been
supported with ECMO, while survival in the 1500
pediatric patients listed in the International Extracor-
poreal Life Support Registry who have received ECMO
for respiratory failure is 53%. Of the 547 adults listed in
the registry, 47% have survived [3].
In general, a primary fungal infection, especially when the
infection is hematogenous, is a contraindication to the use
of ECMO. Historically, patients with hematogenous
fungal infections do poorly on ECMO, primarily because
the mycosis cannot be eradicated from the synthetic sur-
faces of the ECMO circuit. The restriction against ECMO
support for cardiorespiratory failure secondary to fungal
pneumonia without hematogenous spread is less certain.
In theory, this condition should not preclude the use of
ECMO, but no reports about the use of ECMO in this
situation are available.
We report our experience with the use of ECMO to
support a previously healthy adolescent with respiratory
failure secondary to blastomycosis pneumonia to raise
awareness of this disease as a cause of pneumonia and
better understand the use and limitation of extracorporeal
support in this condition.
ARDS = acute respiratory distress syndrome; ECMO = extracorporeal membrane oxygenation; PaCO2 = arterial partial pressure of carbon dioxide;
PaO2 = arterial partial pressure of oxygen; OI = oxygenation index; MAP = mean airway pressure; FiO2 = fraction of inspired oxygen concentration.Case summary
A 15-year-old, 100kg black male developed fever, cough,
and headache 12days prior to admission to Georgetown
University Hospital. Prior to this, the patient had been in
good health with no evidence of immunodeficiency.
There was no history of unusual travel or exposure to
unusual environments. He was treated with amoxicillin for
presumed sinusitis but his symptoms persisted and he was
hospitalized for 2days with erythromycin treatment for
presumed atypical pneumonia. His chest radiograph
revealed a left lower lobe infiltrate. After hospital dis-
charge, the patient’s private physician prescribed amanta-
dine after his condition failure to improve. The patient
was readmitted to the hospital 3days later with respiratory
distress and complete opacification of the right hemi-
thorax and left lower hemithorax on chest radiograph
(Fig. 1). Emergent intubation and institution of mechani-
cal ventilatory support was performed.
Despite supportive care and the institution of broad-
spectrum antibiotic therapy, the patient’s respiratory
failure progressed. Mean airway pressures of 30–40cmH2O
48h after his readmission were required to maintain arter-
ial partial pressure of carbon dioxide (PaCO2) 70torr and
oxygen (PaO2) 50torr. Calculation of the oxygenation
index (OI), a measure that relates airway pressure and
PaO2 to presumed mortality, revealed that his OI was 36.
OI is the product of mean airway pressure (MAP) and frac-
tion of inspired oxygen concentration (FiO2) divided by
the PaO2 [OI=(MAP×FiO2×100)/PaO2]. Treatment with
inverse ratio ventilation, permissive hypercapnia, prone
positioning and pulmonary surfactant instillation failed to
improve oxygenation.
A tracheal aspirate and subsequent bronchoscopy speci-
men revealed broad-based fungal elements consistent
with  Blastomyces dermatitidis. No other organ involvement
with blastomycosis was evident. Amphotericin B was
added to the treatment regimen. By day 5 of readmission
(day 11 of illness), continued deterioration in respiratory
function led to referral for ECMO rescue.
The patient was transported to Georgetown University
Hospital without complication. Despite multiple manipu-
lations of mechanical ventilatory support (peak inspiratory
pressure to 54cmH2O, peak end-expiratory pressure to
18cm H2O) and a trial of inhaled nitric oxide, the OI
remained >40, PaCO2 >99torr, PaO2 50–75torr and pul-
monary artery pressure more than one-half systemic.
Hemodynamic instability developed, requiring treatment
with dopamine and dobutamine infusions. Progressive
renal insufficiency, as demonstrated by rising creatinine
and the development of anuria, was also present.
In an attempt to provide cardiorespiratory support while
treatment for blastomycosis pneumonia was completed, and
to allow time for potential lung recovery, ECMO was insti-
tuted. Modified venoarterial ECMO was chosen because of
the cardiopulmonary instability of the patient. Cannulation
was achieved using a 29F catheter introduced into the right
femoral vein and a 19F catheter placed into the right
femoral artery. The ECMO circuit has been previously
described [4]. Since adequate ventilation and oxygenation
can be maintained by the ECMO circuit, the peak inspira-
tory pressure, rate, and inspired oxygen concentration can
be reduced to lessen iatrogenic lung injury and to provide a
better environment for potential lung healing.
Initial ECMO flows of 50–60cm3/kg per min maintained
mixed venous oxygen saturations of >70% and allowed a
reduction in ventilator settings. After 24h stabilization,
the patient underwent bronchoscopy, which revealed
denuded airway mucosa and purulent material filling the
airways. Over the next few days, repeat bronchoscopy was
performed to remove debris. On ECMO day 3, the patient
became hyperdynamic and developed leukocytosis and
decreasing mixed venous oxygen saturations. Sepsis was
presumed, although cultures remained sterile. Membrane
oxygenators on the ECMO circuit were changed without
complication. The patient continued to have episodes of
decreased mixed venous oxygen saturation despite
increased ECMO circuit flow. Restriction of additional
increases in circuit flow over the next few days led to the
placement of a right internal jugular venous cannula and
right carotid arterial cannula on ECMO day 10. All other
organ systems remained intact and all cultures (blood,
bronchial washing and tissue, urine) remained sterile. The
patient was responsive to commands and questions while
pharmacologic sedation was maintained. By ECMO day
92 Critical Care 1999, Vol 3 No 4
Figure 1
Chest radiograph on day of intubation. Note consolidation of right
hemithorax and left lower thorax.14, minimal clearing of right and left lung fields was noted
with concurrent increases in exhaled tidal volumes. Bron-
choscopy was performed to remove airway debris with
good results over the next few days and efforts to slowly
re-expand the lungs were initiated. On ECMO day 18,
bilateral tension pneumothoraces developed and the
patient suffered cardiac arrest. Despite prompt resuscita-
tion and continued support with ECMO, the patient dete-
riorated over the next 24h and ECMO support was
electively withdrawn. Native pulmonary function was
insufficient and the patient expired.
Postmortem findings
Despite systemic antifungal therapy and extracorporeal
life support, postmortem examination revealed almost
complete replacement of normal lung parenchyma with
fungal elements and chronic inflammatory reaction.
Extensive necrosis, acute and chronic inflammatory cells,
abscesses, fibrin deposition and hemorrhage were seen
(Fig. 2). Broad-based budding fungal organisms consistent
with Blastomyces dermatitidis are seen in Figure 2 through-
out the lung parenchyma. They are not seen in association
with vascular structures. The left lung had regions of
interstitial fibrosis. The central nervous system showed
multiple areas of acute infarction and global ischemic
encephalopathy. No evidence of invasion by Blastomyces
dermatitidis was noted in the bloodstream or in any other
organs outside of the lungs. The final pathologic cause of
death was listed as fungal pneumonia with extensive
destruction of lung tissue.
Comments
Unlike many fungal infections, blastomycosis often occurs
in immunocompetent hosts and many persons recover
without antifungal treatment [5]. The typical patient with
blastomycosis is male, aged 25–50 years, and habitually
exposed to the outdoor environment. Children are rarely
diagnosed with blastomycosis (epidemics excepted). The
occurrence of blastomycosis in this patient, without living
in an endemic area or with a history of prolonged outdoor
activity, is extremely unusual.
The development of ARDS in association with pulmonary
blastomycosis is exceedingly rare. However, when it does
occur, mortality rates have been reported to be 50–80%. It
is likely that this rate of mortality is reduced with prompt
recognition of the disease, aggressive supportive therapies,
and administration of a total of 2g amphotericin B [1,6].
Our patient was referred to us as a potential candidate for
ECMO. Historical data (respiratory failure unresponsive
to conventional therapies and an OI >40) suggested that
this patient had a mortality risk of >80% [4]. In our experi-
ence with pediatric respiratory failure, patients receiving
mechanical ventilation for less than 7days prior to ECMO
initiation have a 67% survival rate.
In general, ECMO is not utilized during an active fungal
infection, since fungal elements in the bloodstream
adhere to the synthetic elements of the ECMO circuit,
making it impossible to eradicate them with antifungal
agents. Pulmonary blastomycosis, however, is often local-
ized to the respiratory tract, making contamination of the
ECMO circuit less likely. Since this patient was previ-
ously healthy, had single-organ disease and had failed less
invasive forms of pulmonary support, ECMO was insti-
tuted to limit further iatrogenic lung injury from mechani-
cal ventilation during completion of amphotericin B
treatment. Despite ECMO support, eradication of blasto-
mycosis and healing of diseased lung tissue did not occur
and the patient did not survive.
While blastomycosis was never isolated from the blood-
stream and was only isolated from the respiratory tract
prior to institution of amphotericin B therapy, it was iden-
tified throughout the lungs on postmortem examination.
In otherwise healthy individuals, it is common to see lung
recovery after treatment with systemic antifungal therapy.
In fact, treatment with oral antifungal agents is sufficient
for organism eradication and pulmonary recovery in most
cases of blastomycosis [7].
There are several potential explanations for this lack of
response to antifungal therapy. One explanation is that
ECMO itself impacted on the effectiveness of antifungal
therapy. Venoarterial ECMO has been shown to reduce
pulmonary blood flow at high levels of bypass, and there is
experimental evidence of pulmonary capillary bed
ischemia with total bypass [8]. In this situation, severe lung
injury may occur. Another potential problem with high
levels of bypass is the potential limitation of drug delivery
to the infected area; inadequate pulmonary blood flow
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Figure 2
Section of lung tissue from post-mortem examination. H/E stain,
magnification 200×. Note multinucleated giant cells consistent with
blastomycosis and extensive destruction of lung.reaching the lungs will lead to impaired fungal eradication.
In this case, however, care was taken to limit the extent of
cardiopulmonary bypass and to maintain pulmonary blood
flow. It is possible that local blood flow was limited by
tissue and vascular injury from the pneumonia, resulting in
subtherapeutic tissue levels of amphotericin B. This would
be consistent with the pathologic findings of heavy con-
centrations of fungal elements in injured lung parenchyma
that was not in proximity to normal vascular structures.
Another potential pitfall of ECMO is the capacity of the
membrane oxygenators to remove certain medications [9].
We monitored serum levels of amphotericin B in the
patient and the ECMO circuit for standard peak and
trough drug levels and when components of the circuit
were changed. All levels were within or exceeded the rec-
ommended therapeutic range and were not affected by
changes of the membrane oxygenator or circuit tubing [10].
It is also possible that this case was referred for ECMO too
late in the course of disease to achieve any substantial
benefit with the ‘lung rest’ provided by ECMO.
In summary, we present the first description of the use of
ECMO to support respiratory failure in an adolescent with
ARDS secondary to blastomycosis pneumonia. Despite the
use of adequate antifungal agents, the reduction of ventila-
tory settings to non-toxic ranges, and adequate oxygen
delivery to other organ systems, eradication of the blasto-
mycosis did not occur and no lung recovery took place.
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